GAMMA Investing LLC Has $39,000 Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

GAMMA Investing LLC boosted its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 131.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 118 shares of the biopharmaceutical company’s stock after buying an additional 67 shares during the quarter. GAMMA Investing LLC’s holdings in Madrigal Pharmaceuticals were worth $39,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of MDGL. Pitcairn Co. increased its holdings in shares of Madrigal Pharmaceuticals by 3.2% during the fourth quarter. Pitcairn Co. now owns 1,060 shares of the biopharmaceutical company’s stock worth $327,000 after purchasing an additional 33 shares during the period. Centaurus Financial Inc. increased its holdings in shares of Madrigal Pharmaceuticals by 12.9% during the fourth quarter. Centaurus Financial Inc. now owns 690 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 79 shares during the period. Parallel Advisors LLC increased its holdings in shares of Madrigal Pharmaceuticals by 42.7% during the first quarter. Parallel Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 85 shares during the period. Arizona State Retirement System increased its holdings in shares of Madrigal Pharmaceuticals by 2.5% during the fourth quarter. Arizona State Retirement System now owns 3,774 shares of the biopharmaceutical company’s stock worth $1,165,000 after purchasing an additional 91 shares during the period. Finally, Farther Finance Advisors LLC increased its holdings in shares of Madrigal Pharmaceuticals by 825.0% during the first quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 99 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 5th. JMP Securities reissued a “market outperform” rating and issued a $443.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Thursday, April 24th. UBS Group lifted their price objective on shares of Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. B. Riley reissued a “buy” rating and issued a $460.00 price objective (up from $422.00) on shares of Madrigal Pharmaceuticals in a research note on Friday, May 2nd. Finally, Canaccord Genuity Group lifted their price objective on shares of Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $420.63.

Madrigal Pharmaceuticals Stock Performance

Shares of Madrigal Pharmaceuticals stock opened at $314.64 on Friday. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $200.63 and a fifty-two week high of $377.46. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.91 and a quick ratio of 5.58. The firm has a market capitalization of $6.99 billion, a P/E ratio of -17.43 and a beta of -1.05. The company’s 50 day moving average price is $288.60 and its two-hundred day moving average price is $311.72.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($3.32) EPS for the quarter, topping analysts’ consensus estimates of ($3.62) by $0.30. The company had revenue of $137.25 million for the quarter, compared to analyst estimates of $112.79 million. Madrigal Pharmaceuticals had a negative net margin of 123.38% and a negative return on equity of 50.54%. During the same quarter in the previous year, the business earned ($7.38) earnings per share. On average, equities analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.